Literature DB >> 26151954

Bioabsorbable vascular scaffold overexpansion: insights from in vitro post-expansion experiments.

Nicolas Foin1, Renick Lee, Alessio Mattesini, Gianluca Caiazzo, Enrico Fabris, Ismail Dogu Kilic, Jing Ni Chan, Yingying Huang, Subbu S Venkatraman, Carlo Di Mario, Philip Wong, Holger Nef.   

Abstract

AIMS: While bioresorbable vascular scaffolds (BVS) are increasingly used in clinical practice, their behaviour when post-dilated beyond their recommended maximum overexpansion diameter remains sparsely documented. We aimed to test the overexpansion of the BVS scaffold in vitro and evaluate the impact of excessive scaffold oversizing on focal point support. METHODS AND
RESULTS: We examined the post-expansion behaviour of the bioresorbable vascular scaffold (3.0 mm and 3.5 mm Absorb BVS; Abbott Vascular, Santa Clara, CA, USA) after overexpansion with non-compliant (NC) balloons of increasing diameters. After each oversizing step, the scaffolds were measured and inspected for strut disruption using microscope and optical coherence tomography imaging. Point force mechanical measurements on single scaffold struts were also performed to evaluate the impact of excessive scaffold overstretching on focal mechanical support. 3.0 mm and 3.5 mm scaffold sizes could be post-expanded up to 1 mm above their nominal diameters without any strut fracture when deployed without an external constraining model. Importantly, when overexpansion of both scaffold sizes was repeated using a constraining silicone lesion model, only post-expansion with an NC balloon size 0.5 mm larger than the scaffold nominal sizes could be performed without strut fractures. Point force compression analysis on single struts shows that overstretched struts with fractures provided lower focal strength compared to overexpanded ring segments without fractures and normal segments expanded at nominal pressure.
CONCLUSIONS: In our experiments, only overexpansion with an NC balloon 0.5 mm larger than the BVS size was feasible for BVS deployed inside an arterial lesion model. Overexpansion of the BVS scaffold beyond recommended post-dilation limits can lead to strut disconnections and focal loss of mechanical support.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26151954     DOI: 10.4244/EIJY15M07_02

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  4 in total

Review 1.  The DESolve novolimus bioresorbable Scaffold: from bench to bedside.

Authors:  Alessio Mattesini; Simone Bartolini; Carlotta Sorini Dini; Serafina Valente; Guido Parodi; Miroslava Stolcova; Francesco Meucci; Carlo Di Mario
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

2.  Off-label indications for bioresorbable scaffolds: "Beethoven can, but you cannot".

Authors:  Juan Luis Gutiérrez-Chico; Undine Ella Witt; Milosz Jaguszewski
Journal:  Postepy Kardiol Interwencyjnej       Date:  2016-02-11       Impact factor: 1.426

3.  Comparison of a Drug-Free Early Programmed Dismantling PDLLA Bioresorbable Scaffold and a Metallic Stent in a Porcine Coronary Artery Model at 3-Year Follow-Up.

Authors:  Kazuyuki Yahagi; Yi Yang; Sho Torii; Johanne Mensah; Roseann M White; Marion Mathieu; Erica Pacheco; Masataka Nakano; Abdul Barakat; Tahmer Sharkawi; Michel Vert; Michael Joner; Aloke V Finn; Renu Virmani; Antoine Lafont
Journal:  J Am Heart Assoc       Date:  2017-06-09       Impact factor: 5.501

4.  Mechanical performance and healing patterns of the novel sirolimus-eluting bioresorbable Fantom scaffold: 6-month and 9-month follow-up by optical coherence tomography in the FANTOM II study.

Authors:  Jo Krogsgaard Simonsen; Emil Nielsen Holck; Didier Carrié; Norbert Frey; Matthias Lutz; Joachim Weber-Albers; Dariusz Dudek; Bernard Chevalier; Joost Daemen; Jouke Dijkstra; Camilla Fox Maule; Omeed Neghabat; Jens Flensted Lassen; Jeffrey Anderson; Evald Høj Christiansen; Alexandre Abizaid; Niels Ramsing Holm
Journal:  Open Heart       Date:  2019-02-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.